These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
45. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [TBL] [Abstract][Full Text] [Related]
46. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Boots JM; van Duijnhoven EM; Christiaans MH; Nieman FH; van Suylen RJ; van Hooff JP Transpl Int; 2001 Dec; 14(6):370-83. PubMed ID: 11793034 [TBL] [Abstract][Full Text] [Related]
47. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: paired kidney analysis. Cheung CY; Chan HW; Liu YL; Chau KF; Li CS Nephrology (Carlton); 2009 Dec; 14(8):758-63. PubMed ID: 20025685 [TBL] [Abstract][Full Text] [Related]
48. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Solez K; Vincenti F; Filo RS Transplantation; 1998 Dec; 66(12):1736-40. PubMed ID: 9884269 [TBL] [Abstract][Full Text] [Related]
49. Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. Jiang H; Sakuma S; Fujii Y; Akiyama Y; Ogawa T; Tamura K; Kobayashi M; Fujitsu T Transpl Int; 1999; 12(2):92-9. PubMed ID: 10363590 [TBL] [Abstract][Full Text] [Related]
50. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. Ye F; Ying-Bin X; Yu-Guo W; Hetzer R J Heart Lung Transplant; 2009 Jan; 28(1):58-66. PubMed ID: 19134532 [TBL] [Abstract][Full Text] [Related]
51. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Stoves J; Newstead CG; Baczkowski AJ; Owens G; Paraoan M; Hammad AQ Nephrol Dial Transplant; 2004 Aug; 19(8):2113-20. PubMed ID: 15161956 [TBL] [Abstract][Full Text] [Related]
52. Molecular and structural consequences of early renal allograft injury. Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412 [TBL] [Abstract][Full Text] [Related]
53. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation. Batista F; Auyanet I; Torregrosa JV; Oppenheimer F Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461 [TBL] [Abstract][Full Text] [Related]
54. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients. Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523 [TBL] [Abstract][Full Text] [Related]
55. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766 [TBL] [Abstract][Full Text] [Related]
56. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. El-Agroudy AE; El-Dahshan K; Mahmoud K; El-Baz M; Shokeir AA; Ghoneim MA Ann Transplant; 2008; 13(4):46-54. PubMed ID: 19034223 [TBL] [Abstract][Full Text] [Related]
57. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF; Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398 [TBL] [Abstract][Full Text] [Related]
58. Tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: the EURO-SPK 3-year results. Malaise J; Saudek F; Boucek P; Adamec M; Van Ophem D; Squifflet JP; Transplant Proc; 2005; 37(6):2843-5. PubMed ID: 16182828 [TBL] [Abstract][Full Text] [Related]
59. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259 [TBL] [Abstract][Full Text] [Related]
60. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]